Saudi SFDA Launches NADR Program to Accelerate Rare Disease Drug Access

The Saudi Food and Drug Authority has introduced the New Accelerator Program for Drugs in Rare Diseases, known as NADR, to support the development, registration, and faster availability of medicines for rare conditions.

The initiative is intended to strengthen cooperation among regulators, researchers, pharmaceutical companies, and innovators while helping eligible patients gain earlier access to promising treatments.

Dedicated Framework for Rare Disease Medicines

The NADR program covers medicines designed to treat or prevent rare diseases affecting fewer than five people per 10,000 in Saudi Arabia.

Eligible products must address a significant treatment gap. They may be considered when no effective therapy is available or when the medicine offers a meaningful clinical advantage over existing options.

The framework applies to products still under development as well as medicines approved by another regulatory authority but not yet registered in Saudi Arabia.

Regulatory Support for Developers

The SFDA will provide scientific and regulatory assistance to developers working on rare disease medicines. The support package is designed to reflect the challenges of researching conditions that affect small patient populations.

Key measures include:

• Guidance on scientific and regulatory requirements.

• Flexible approaches for preparing and assessing clinical evidence.

• Evaluation methods that consider the limited number of eligible patients.

• Adaptable procedures for registering manufacturing facilities.

• Assistance with periodic safety reporting requirements.

These measures are intended to improve the development pathway while maintaining appropriate standards for medicine quality, safety, and effectiveness.

Faster Access to Promising Treatments

The SFDA has identified faster access to rare disease medicines as a key priority. Through NADR, the authority aims to shorten regulatory timelines for suitable products and increase treatment choices for people living with serious and uncommon conditions.

The program may also help address research gaps by encouraging innovators to develop therapies for diseases that have traditionally attracted limited commercial investment.

Supporting Innovation in Saudi Healthcare

The launch of NADR forms part of Saudi Arabia’s broader healthcare transformation agenda. The program supports the objectives of the Health Sector Transformation Program and Saudi Vision 2030, including improved care quality, stronger innovation, and better patient outcomes.

By creating a dedicated pathway for rare disease medicines, the SFDA aims to make Saudi Arabia a more attractive environment for pharmaceutical research and development.